fbpx

American Bone Health has closed.  However, on October 1, 2023, we joined forces with the Bone Health and Osteoporosis Foundation (BHOF) so that BHOF could continue offering all of the important programs and services created by American Bone Health. Please visit www.bonehealthandosteoporosis.org for more information about the Bone Health and Osteoporosis Foundation.

Corporate Partners

Our corporate partners support us with unrestricted financial contributions.

More importantly, they provide strategic business advice to help us meet our mission to educate the public about bone health.

Click on the links to the company websites for more information about their products and services. American Bone Health does not maintain
a list of treatment providers or locations.

Medimaps Group is a leading medical software company developing tissue/bone microarchitecture medical imaging software analytics with Artificial Intelligence capabilities. Our proven technology helps doctors make improved clinical decisions for the patients.  Our flagship product, TBS Osteo (iNsight™) software application, has been used for years in DXA clinical practice to better predict fracture risk in the field of osteoporosis. It has become the gold standard for bone structure assessment in routine clinical practice.

Alexion new logo

Alexion has a focus on treating rare diseases, including hypophosphatasia (HPP). HPP is a genetic, chronic, progressive, and life-threatening metabolic disease. HPP is characterized by low alkaline phosphatase (ALP) activity and defective bone mineralization that can lead to destruction and deformity of bones and other skeletal abnormalities, as well as systemic complications such as muscle weakness and respiratory failure leading to premature death in infants.

Ultragenyx is a biopharmaceutical company working on treatments for rare and ultra-rare diseases, with a focus on genetic diseases. Their drug Crysvita®  (burosumab) is approved for 1) the treatment of X-linked hypophosphatemia (XLH), a disorder of the phosphate-regulating gene and 2) tumor-induced osteomalacia (softening of the bones) caused by high levels of FGF23, that is tied to low phosphate levels.

AgNovos logo

AgNovos Healthcare is a medical technology company developing new therapies that leverage proprietary, bone-building technology and regenerative medicine to address unmet needs in the treatment of bone disease. AgNovos Healthcare is privately held and has its corporate headquarters in New York City with manufacturing, research & development, and corporate support services located in Rockville, MD.

AMGEN logo

Amgen is a leading human therapeutics company in the biotechnology industry. For more than 25 years, the company has tapped the power of scientific discovery and innovation to advance the practice of medicine. Today, as a Fortune 500 company serving millions of patients, Amgen continues to be an entrepreneurial, science-driven enterprise dedicated to helping people fight serious illness.

Join Our Corporate Advisory Board

Our Corporate Advisors are industry leaders working with us to meet our mission of educating the public about bone health and fracture prevention. The Corporate Advisory Board helps shape the future of bone health, expand our national outreach, and partner with us on national community-based programs. Together we disseminate public health messages and tools for better bone health, provide improved access to quality care, and advocate for policies that support healthy bones for all.